Product Monograph Template - Schedule D]
video-placeholder-01.png
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva gets EU nod for severe asthma drug Cinqaero - PMLiVE
CINQAIR® (reslizumab) Injection – About Asthma Control
Medication Detail
761033Orig1s000
FDA Approves Cinqair To Treat Severe Asthma - Pharmacy Practice News
including co-pays, co-insurance, and deductibles.*
Dosing and Administration
Attachment: Product Information: Reslizumab
Drug Analysis: Cinqair - Research and Markets
Administering CINQAIR.
Reslizumab | New Drug Approvals
Israeli Pharma gets FDA Approval for Asthma Antibody
Flopped trials dash Teva's hopes of battling GSK, AZ with subcutaneous Cinqair | Fierce Pharma
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Reslizumab (Cinqair) Approved to Treat Severe Asthma | RT
Clinical Efficacy Guidelines
test-placeholder-02.png
CINQAIR® (reslizumab) Injection – About Asthma Control
CINQAIR® (reslizumab) Injection – About Asthma Control
CINQAIR® (reslizumab) Injection - Savings and Support
